NEW YORK (360Dx) – Quidel announced after the close of the market on Monday changes to its reporting segments.
During the fourth quarter, the company changed its presentation of revenue to "reflect how management strategically thinks about the business categories," it said in a statement. Revenues for the QuickVue and Sofia businesses will be reported within Quidel's immunoassay category, while Solana AmpliVue, and Lyra products will be reported in its molecular category.
Quidel's Thyretain and Diagnostic Hybrids revenues will be reported in the firm's virology category, and the Specialty Products Group will be reported in the Specialty Products category.
"Our traditional reporting categories, such as infectious disease and women's health, for example, were historically useful, but this new approach we believe more accurately reflects how we think about the strategic components of the broader business, especially key pieces of the business, like our immunoassay or molecular product categories," Quidel President and CEO Douglas Bryant said in a statement.